Chelmow David
Virginia Common Wealth University Medical Centre, Richmond, USA.
BMJ Clin Evid. 2011 Apr 4;2011:1410.
Loss of more than 500 mL of blood following childbirth is usually caused by failure of the uterus to contract fully after delivery of the placenta, and occurs in over 10% of deliveries, with a 1% mortality rate worldwide. Other causes of postpartum haemorrhage include retained placental tissue, lacerations to the genital tract, and coagulation disorders. Uterine atony is more likely in women who have had a general anaesthetic or oxytocin, an over-distended uterus, a prolonged or precipitous labour, or who are of high parity.
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of non-drug interventions and of drug interventions to prevent primary postpartum haemorrhage? We searched: Medline, Embase, The Cochrane Library, and other important databases up to March 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
We found 40 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
In this systematic review we present information relating to the effectiveness and safety of the following interventions: active management of the third stage of labour, carboprost injection, controlled cord traction, ergot compounds (ergometrine/methylergotamine), immediate breastfeeding, misoprostol (oral, rectal, sublingual, or vaginal), oxytocin, oxytocin plus ergometrine combinations, prostaglandin E2 compounds, and uterine massage.
产后失血超过500毫升通常是由于胎盘娩出后子宫未能充分收缩所致,在超过10%的分娩中会发生,全球死亡率为1%。产后出血的其他原因包括胎盘组织残留、生殖道裂伤和凝血障碍。接受全身麻醉或使用催产素、子宫过度扩张、产程延长或急产、或多胎妊娠的女性更易发生子宫收缩乏力。
我们进行了一项系统综述,旨在回答以下临床问题:非药物干预和药物干预对预防原发性产后出血有何效果?我们检索了:截至2010年3月的Medline、Embase、Cochrane图书馆及其他重要数据库(Clinical Evidence综述会定期更新;请查看我们的网站获取本综述的最新版本)。我们纳入了来自美国食品药品监督管理局(FDA)和英国药品及医疗保健产品监管局(MHRA)等相关组织的危害警示。
我们找到了40项符合我们纳入标准的系统综述、随机对照试验或观察性研究。我们对干预措施的证据质量进行了GRADE评估。
在本系统综述中,我们提供了以下干预措施的有效性和安全性相关信息:第三产程的积极管理、卡前列素注射、控制脐带牵拉、麦角化合物(麦角新碱/甲基麦角新碱)、立即母乳喂养、米索前列醇(口服、直肠、舌下或阴道给药)、催产素、催产素加麦角新碱联合用药、前列腺素E2化合物及子宫按摩。